×
For best experience we recommend to activate Javascript in your browser.
Recombinant CTLA-4 (Ipilimumab Biosimilar) antibody
Reactivity: Human
FACS, ELISA, BLI, Func, SPR
Host: Human
Monoclonal
unconjugated
Recombinant Antibody
Product Details anti-CTLA-4 (Ipilimumab Biosimilar) Antibody
(hide)
Target
See all CTLA-4 (Ipilimumab Biosimilar) products
CTLA-4 (Ipilimumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for CTLA-4 (Ipilimumab Biosimilar) antibodies
Human
Expression System
CHO Cells
Clonality
All clonalities for CTLA-4 (Ipilimumab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for CTLA-4 (Ipilimumab Biosimilar) antibodies
This CTLA-4 (Ipilimumab Biosimilar) antibody is un-conjugated
Application
Flow Cytometry (FACS), ELISA, Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Purpose
Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab)
Characteristics
Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.2 kDa.
Purity
>95 %
Isotype
IgG1
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for CTLA-4 (Ipilimumab Biosimilar)
(hide)
Target
CTLA-4 (Ipilimumab Biosimilar)
Abstract
CTLA-4 (Ipilimumab Biosimilar) Products
Target Type
Biosimilar
Molecular Weight
145.2 kDa
UniProt
P16410
Recently viewed
(hide)